Er det ikke det som skal informeres om i dagens presentasjon da?
Jo, og i biotek er det Ă„penbart asset og hovedvirksomhet i mine Ăžyne og skal deles med markedsaktĂžrer.
Helt standard biotek virksomhet
Og om Cevira. Lovende kommentar fra Asieris:
«Breaking News! Our multinational Phase III Clinical Study hits the mark! The world is one step closer to a non-vaccine treatment for cervical HSIL: ow.ly/iIOZ50PP27p #asieris #clinicaltrial #phaseIII #cervical #HSIL»
Hva tenker du @Savepig nÄr selskapet gÄr ut slik med Cevira og Hexvix resultater i fase III studiene?
Og der kom pressemeldingen!
1 Like
Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress
Press Release â Oslo, Norway, October 12, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has today unveiled the results of its HexvixÂź (APL-1706) Phase III clinical trial in China. A presentation scheduled for today at the 43rd Congress of the SociĂ©tĂ© Internationale dâUrologie (SIU), confirms that, in a Chinese population, Hexvix blue light cystoscopy (BLCÂź) outperformed white light cystoscopy (WLC) in the detection of bladder cancer, particularly in cases of carcinoma in situ (CIS), and exhibited good tolerability.
The highly statistically significant results corroborate the findings of Photocureâs own randomized controlled trials (RCTs) that demonstrate the clinical benefits of Hexvix BLC over WLC, specifically superior tumor detection and a favorable tolerability profile with no serious adverse events. Moreover, Asierisâ Phase III Hexvix trial is the first RCT conducted with high definition 4K blue light capital equipment.
âThis randomized-controlled trial reinforces the benefits of BLC with Hexvix in tumor detection over WLC alone with clinically convincing and statistically significant results. This is on the backdrop of this Chinese trial being the first RCT conducted with 4K high definition (HD) blue light equipment, making it a valuable addition to the body of evidence already available on BLC with Hexvix. It confirms that BLC with Hexvix is additive to WL also with high quality HD imaging technology. We are pleased to see and acknowledge that our partners at Asieris are driving innovation to support unmet needs in bladder cancerâ , said Anders Neijber, Photocureâs Chief Medical Officer.
The trial results have been selected as a âlate-breaking abstractâ at the 43rd Congress of the SociĂ©tĂ© Internationale dâUrologie (SIU) in Istanbul, Turkey, October 11-14. The clinical study data will be presented today, October 12, in the form of an Oral ePoster at 1:45pm local time.
The study is a prospective, self-controlled, multicenter Phase â ą study intended to evaluate the safety and detection benefits of blue light cystoscopy (BLCÂź) with Hexvix compared to white light cystoscopy (WLC) in the diagnosis of non-muscle invasive bladder cancer (NMIBC) in a Chinese population. The study included a total of 158 patients, of which 114 underwent BLC. Of the 97 patients diagnosed with NMIBC, a total of 42 patients (43.3%) had one or more additional lesions detected with Hexvix BLC compared to WLC (p<0.0001). Among the 114 patients, 11.4% (13/114) had CIS lesions, and among these, 11 patients (84.6%, 11/13) had additional CIS lesions detected under Hexvix BLC that were not found under WLC. The detection rates for PUNLMP, CIS, Ta, T1, and T2-T4 tumor lesions in the BLC group were NA, 94.7%, 100%, 98.2%, and 100%, respectively, while in the WLC group, they were NA, 42.1%, 76.1%, 91.2%, and 100%, respectively.
Read Asierisâ full media release here: Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress - Asieris Pharmaceuticals
Asieris Pharmaceuticals is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases.
In January 2021, Asieris entered into a license agreement with Photocure ASA to obtain the exclusive registration and commercialization rights of Hexvix in mainland China and Taiwan.
14 Likes
Bare Ă„ skyndte seg Ă„ sell on news i dag 
Bare la de selge, sÄ aksjene bytter hender til folk som Þnsker Ä vÊre langsiktige.
1 Like
The study included a total of 158 patients, of which 114 underwent BLC. Of the 97 patients diagnosed with NMIBC, a total of 42 patients (43.3%) had one or more additional lesions detected with Hexvix BLC compared to WLC (p<0.0001). Among the 114 patients, 11.4% (13/114) had CIS lesions, and among these, 11 patients (84.6%, 11/13) had additional CIS lesions detected under Hexvix BLC that were not found under WLC. The detection rates for PUNLMP, CIS, Ta, T1, and T2-T4 tumor lesions in the BLC group were NA, 94.7%, 100%, 98.2%, and 100%, respectively, while in the WLC group, they were NA, 42.1%, 76.1%, 91.2%, and 100%, respectively.
Dette er de beste tallene jeg har sett vs WLC. Tidligere har de brukt Ä ligge pÄ 30% sÄnn ca mener jeg Ä huske.
10 Likes
Algoene jobber pÄ spreng med Ä fÄ deg til Ä selge aksjene dine, ved Ä la deg tro at den faller tilbake grunnet dÄrlige resultater. Helt ufattelig at de fÄr det til.
Bare Ă„ sitte i ro, amigos y amigas.
3 Likes
Det er det som stadig skjer i denne aksjen. Mulig det er mer lÞnnsomt? Vi fÄr vente Ä se.
1 Like
La nÄ resultatene synke inn og presentasjonen gjennomfÞres i det internasjonale markedet / konferansen. Gode resultater slÄr aldri feil
Det sees i Ultimovacs (shortere forsĂžker smarte handler) men blir knust av gode resultater. At noen kanskje forsĂžker Ă„ stagge kurs for Ă„ tjene penger i short innen biotekverden hvor pasienter er avhengig av risikokapital for Ă„ fremme nye lĂžsninger er en STOR uting.
Hvis Janus eller andre forsÞker seg med short i Photocure hÄper jeg det blir en blemme av de sjeldne
2 Likes
Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, âAPL-1706 is currently the only approved optical imaging for assisting in the diagnosis and surgery of bladder cancer worldwide. The data presented at the SIU conference further validates the tremendous clinical value of APL-1706. We believe that this innovative drug will bring significant benefits to bladder cancer patients in the local market. We will actively advance the related regulatory submissions in China, expediting its market entry to benefit more patients as soon as possible.â
5 Likes
We believe that this innovative drug will bring significant benefits to bladder cancer patients in the local market. We will actively advance the related regulatory submissions in China, expediting its market entry to benefit more patients as soon as possible.â
7 Likes
Litt uheldig at Ultimovacs slapp resultater i dag, mye âsidelined moneyâ som kunne gĂ„tt inn i Pho, som gikk inn i Ulti. Kan se ut som norske biotek fans er all in nĂ„ 
1 Like
Markedet sender kursen nedâŠvrient Ă„ forstĂ„ seg pĂ„ dette. Ikke bra nok til Ă„ danke ut hvitt lys? Markedet er redd for samme situasjon som i USA?
Beklager, skjÞnner ikke hvilken planet du er pÄ.
Markedet sender akkurat nÄ verdiene opp. Og like gjerne ender kursen langt opp allerede i dag. Hva er riktig kurs skjer plutselig og gjerne over tid. Ville noen lÞftet Þyenbryn om kursen i dag var over 100kr?
«âŠ.expediting its market entry to benefit more patients as soon as possible.â
1 Like
Denne gjengen er pÄ SIU sammen med alle verdens urologer, klart vi skal kraftig opp den kommende tiden.
3 Likes
Sorry bare skjĂžnte ikke hvorfor ikke markedsreaksjonen ble en annen. Kursen var hĂžyere rett fĂžr enn rett etter
Trenger ikke beklage. Og det stemmer ikke. Kursen var ikke hÞyere rett fÞr. Etter melding i dag har kursen vÊrt oppe i 59,8 og dagen er ung. Og kanskje er fremtiden ikke sÄ vÊrst likevel? @Bingo123 det er vel ikke hverdagskost i norsk biotek at det snakkes om expediting its market entry?
Resultatene er kjent og blir sikkert diskutert av aktĂžrer i innlegget over. Stor interesse for selskapet i dag, se omsetning mot markedsverdi. Ultimovacs bykser og Photocure opp ca 30% siste mnd. Det er jo en start og positiv trend?
Alt annet likt, enkelt Ă„ se lysere pĂ„ femtiden med Asieris sine fremlagte resultater i meldingen og underbygges av deres kommentar om expediting its market entry to benefit more patients as soon as possible.â
2 Likes
PÄ tide med nye analyser fra meglerhusene? For Ä fÄ ett riktig bilde av potensialet til Photocure burde de ogsÄ ta Cevira med i betraktningen. 
3 Likes